Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CASP10
REST API REST API
Homo sapiens
CASP10 is differentially expressed in 300 experiments: 155 organism parts: bone marrow, liver, ... (153 more);, 244 disease states: normal, chronic myelogenous leukemia, ... (242 more);, 95 cell types 393 cell lines 44 compound treatments and 74 other conditions.
Synonyms MCH4
Orthologs Dcp-1 (Drosophila melanogaster)   decay (Drosophila melanogaster)   casp8 (Danio rerio)   casp8l1 (Danio rerio)   Ice (Drosophila melanogaster)   F7BL88_CIOIN (Ciona intestinalis)   F1P102_CHICK (Gallus gallus)   casp10 (Xenopus laevis)   CASP10 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, plasma membrane, protein binding, apoptosis, innate immune response, peptidase activity, induction of apoptosis, cysteine-type endopeptidase activity, proteolysis, cysteine-type peptidase activity, regulation of apoptosis, positive regulation of I-kappaB kinase/NF-kappaB cascade, induction of apoptosis by extracellular signals
InterPro Term Pept_C14_p10, Pept_C14_ICE_p20, Pept_C14_p45_core, Pept_C14_cat, DED
UniProt Accession Q92851, Q68HC0, B4E3T5
Gene-Disease Assocation LYMPHOMA, NON-HODGKIN, FAMILIAL, GASTRIC CANCER, GASTRIC CANCER, HEREDITARY DIFFUSE; HDGC, AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IIA; ALPS2A
Search EB-eye ENSG00000003400
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-3526, E-MTAB-62, E-GEOD-8167, ... (31 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (42 experiments)

Factor Value U/D Experiments
HL-60
3
E-GEOD-5258, E-GEOD-96, E-MTAB-37
MDAMB175VII
2
E-MTAB-37, E-MTAB-62
CCRFCEM
2
E-GEOD-24147, E-MTAB-37
DU145
2
E-GEOD-17482, E-GEOD-20089
Jurkat
2
E-GEOD-1880, E-MEXP-2197
MOLT4
2
E-MTAB-62, E-MTAB-37
387 more value(s).


Cell type

studied in E-GEOD-22529, E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, ... (47 experiments)

Factor Value U/D Experiments
epithelial cell
2
E-GEOD-10797, E-MEXP-2034
CD34+
2
E-AFMX-5, E-TABM-145
CD14+ monocyte
2
E-AFMX-5, E-TABM-145
mononuclear
2
E-GEOD-13987, E-GEOD-26672
721 B lymphoblast
2
1
E-AFMX-5
eosinophil
1
E-GEOD-3982
89 more value(s).


Disease state

studied in E-GEOD-1615, E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-GEOD-16363, ... (66 experiments)

Factor Value U/D Experiments
acute lymphoblastic leukemia
3
E-MTAB-62, E-MTAB-37, E-GEOD-96
colon carcinoma
3
E-MTAB-62, E-GEOD-3726, E-MTAB-37
acute quadriplegic myopathy
2
E-GEOD-3307, E-MTAB-62
AIDS-KS, HIV+, nodular (late) stage
2
2
E-MTAB-62, E-MEXP-66
choriocarcinoma
2
E-MTAB-62, E-MTAB-37
control
2
E-GEOD-20602, E-GEOD-21912
238 more value(s).


Compound treatment

studied in E-GEOD-5258, E-TABM-782, E-GEOD-3720, E-GEOD-5824, E-TABM-868, ... (26 experiments)

Factor Value U/D Experiments
lipopolysaccharide
3
E-MEXP-1958, E-TABM-868, E-GEOD-3720
5-aza-2'-deoxycytidine
3
1
E-MEXP-1269
ponasterone A
1
E-GEOD-3113
interleukin-24 (Homo sapiens)
1
E-GEOD-7216
TTA
1
E-MEXP-2590
potassium dichromate
1
E-GEOD-6907
38 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biosource provider
studied in E-TABM-325, E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-19246, ... (11 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-20033, E-GEOD-6236, E-GEOD-2666, ... (9 experiments)

Dfs follow up
studied in E-GEOD-22541

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, E-TABM-147, E-GEOD-21138 ... (5 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720, E-GEOD-4086

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-7011, E-MTAB-73, E-GEOD-7578, E-GEOD-20847, E-MTAB-108 ... (5 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-17476, E-GEOD-21750, E-GEOD-2292, E-GEOD-18736, ... (11 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-GEOD-12773, E-GEOD-20540, E-MEXP-1446 ... (5 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-MEXP-2069, E-GEOD-1926, ... (44 experiments)

individual id
studied in E-GEOD-19519

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-MEXP-561, E-GEOD-980, ... (6 experiments)

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Localisation of metastases
studied in E-GEOD-22541

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004, E-LGCL-5

Phenotype
studied in E-GEOD-19703, E-GEOD-1493, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, ... (8 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Replicate
studied in E-GEOD-10896

RNAi
studied in E-MEXP-101, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-23984, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-2018, E-GEOD-1926, E-TABM-276, E-GEOD-2748

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-19815

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4271, E-GEOD-3494, E-GEOD-1561, E-TABM-147

Tumor size
studied in E-GEOD-3494

Vehicle
studied in E-GEOD-5258

Processing time: 0.308 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM